Market Overview

Mallinckrodt Spikes On Citron Tweet

Share:
Related VRX
Valeant Surrenders Early Gains After SILIQ's FDA Approval
Wall Street Buys Valeant After Ackman Cuts Stake
This Guru Loves Valeant; Should You? (GuruFocus)
Related
Vetr Crowd Downgrades Mallinckrodt To Hold
Key Presenters At Leerink's Healthcare Conference
The Vetr community has downgraded $MNK to 2.5-Stars (Vetr)

Mallinckrodt PLC (NYSE: MNK) is up roughly 4 percent at $54.80 on Friday.

Contributing to the spike is a tweet from Citron Research, which read: "Clarification: Citron does not recommend short $MNK at $54 for short-term. Wait for fundamentals to ‘kick in' and guide lower –like $VRX."

This is not the first time the stock has moved on Citron news.

Related Link: Citron: Mallinckrodt Makes Valeant Look Like Choirboys

Earlier in the week, an article from The Street cited Citron's Andrew Left commenting on Mallinckrodt and Valeant Pharmaceuticals Intl Inc (NYSE: VRX). According to the article, the analyst called Mallinckrodt the "poster child" for price gouging and stated, "Mallinckrodt is squeaking by without anyone talking about it. Mallinckrodt makes Valeant look like a bunch of choirboys."

Subsequently, Mallinckrodt fell subject to a related selloff.

Posted-In: Andrew Left CitronLong Ideas News Short Ideas Movers Trading Ideas

 

Related Articles (VRX + MNK)

View Comments and Join the Discussion!